Display options
Cite
Smets L, Verbeek J, Korf H, et al. Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. Hepatology. 2021;73(6):2598-2600doi: 10.1002/hep.31613.
Smets, L., Verbeek, J., Korf, H., van der Merwe, S., & Nevens, F. (2021). Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. Hepatology (Baltimore, Md.), 73(6), 2598-2600. https://doi.org/10.1002/hep.31613
Smets, Lena, et al. "Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate." Hepatology (Baltimore, Md.) vol. 73,6 (2021): 2598-2600. doi: https://doi.org/10.1002/hep.31613
Smets L, Verbeek J, Korf H, van der Merwe S, Nevens F. Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. Hepatology. 2021 Jun;73(6):2598-2600. doi: 10.1002/hep.31613. Epub 2021 May 25. PMID: 33140868.
Copy Download .nbib Format: NLM
Share it on

Hepatology. 2021 Jun;73(6):2598-2600. doi: 10.1002/hep.31613. Epub 2021 May 25.

Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate.

Hepatology (Baltimore, Md.)

Lena Smets, Jef Verbeek, Hannelie Korf, Schalk van der Merwe, Frederik Nevens

Affiliations

  1. Laboratory of Hepatology, CHROMETA Department, KU Leuven, Leuven, Belgium.
  2. Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium is part of the Members of the European Reference Networks RARE-LIVER.

PMID: 33140868 DOI: 10.1002/hep.31613

[No abstract available.]

References

  1. Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, et al. Goals of treatment for improved survival in primary biliary cholangitis. Am J Gastroenterol 2020;115:1066-1074. - PubMed
  2. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643. - PubMed
  3. Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018;378:2171-2181. - PubMed
  4. Reig A, Sesé P, Parés A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol 2018;113:49-55. - PubMed

Publication Types